TransCelerate BioPharma Joins SCRS Leadership Council

FOR IMMEDIATE RELEASE
June 5, 2013
Rockville, MD

TransCelerate BioPharma Joins Society for Clinical Research Sites (SCRS) Leadership Council

Non-Profit seeks to develop shared industry solutions to accelerate the development of innovative products.

Rockville, MD, June 5, 2013 –  The Society for Clinical Research Sites (SCRS) is pleased to announce that Dalvir Gill, Ph.D., Chief Executive Officer of TransCelerate BioPharma, has accepted a seat on the SCRS Leadership Council.  The rapidly growing SCRS established the Leadership Council to provide strategic global guidance, policy decisions and oversight for the organization.  Members of the Council are seasoned, committed executives who bring their perspectives and expertise from various segments of the clinical research enterprise.

Christine Pierre, President of SCRS, says.  “Dr. Gill is a key addition to our Leadership Council.  His years of experience in our sector and the fact that he represents TransCelerate, the first industry-wide initiative to join our Council, will be invaluable as SCRS continues building a global organization that gives a voice to clinical research sites. By working together among all the industry stakeholders we are more confident that purposeful change can be achieved.”

TransCelerate BioPharma formed in 2012 by ten founding healthcare and pharmaceutical companies as a non-profit organization focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety.  TransCelerate’s goal is to deliver more high quality medicines to patients faster.  The organization evolved from discussions at various forums for executive R&D leadership to discuss relevant issues facing the industry leading to common solutions.  In April 2013, the organization announced that six more pharmaceutical companies joined as members.

Dr. Gill explains that the mix of companies that have joined TransCelerate are very interested in the perspective that sites can bring to the industry-wide discussion on improving R&D efforts.  “As an organization, TransCelerate has a mission of speeding the delivery of therapies to patients.  To achieve this goal, we need to better understand the site’s issues.  At the same time, I can bring our members’ perspective to the SCRS Leadership Council, and together, we will have input from across the spectrum, enabling all of us to become better informed as we seek solutions to common challenges.  This is a very exciting opportunity for the stakeholders in our industry,” Dr. Gill says.

About SCRS

SCRS is a trade organization representing global clinical research sites representing 1,300 sites in 12 countries in just seven months of its launch. SCRS’ mission is to unify and amplify the voice of the global clinical research site community. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will also benefit from membership.

###

Contact

Denise Davis, Event and Communication Coordinator
Society for Clinical Research Sites
410.696.5080
denise.davis@myscrs.org